Vanguard Group Inc. Boosts Stock Holdings in Aura Biosciences, Inc. (NASDAQ:AURA)

Vanguard Group Inc. boosted its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,917,730 shares of the company's stock after acquiring an additional 112,296 shares during the period. Vanguard Group Inc. owned 3.84% of Aura Biosciences worth $15,764,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. bought a new position in Aura Biosciences during the 4th quarter worth $87,000. AlphaQuest LLC acquired a new stake in shares of Aura Biosciences in the 4th quarter valued at $136,000. Intech Investment Management LLC acquired a new stake in shares of Aura Biosciences in the 4th quarter valued at $172,000. American Century Companies Inc. boosted its holdings in shares of Aura Biosciences by 33.9% in the 4th quarter. American Century Companies Inc. now owns 47,701 shares of the company's stock valued at $392,000 after purchasing an additional 12,081 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Aura Biosciences by 107.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company's stock valued at $477,000 after purchasing an additional 27,718 shares in the last quarter. Institutional investors own 96.75% of the company's stock.

Insider Transactions at Aura Biosciences

In related news, insider Conor Kilroy sold 7,162 shares of Aura Biosciences stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $5.49, for a total value of $39,319.38. Following the completion of the sale, the insider now owns 179,313 shares of the company's stock, valued at approximately $984,428.37. This trade represents a 3.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 14,148 shares of company stock valued at $91,434 in the last quarter. 5.40% of the stock is currently owned by company insiders.

Aura Biosciences Stock Performance

Shares of Aura Biosciences stock traded up $0.19 on Wednesday, hitting $5.90. The stock had a trading volume of 9,229 shares, compared to its average volume of 200,017. The stock has a 50 day moving average of $6.62 and a 200 day moving average of $8.12. Aura Biosciences, Inc. has a twelve month low of $4.30 and a twelve month high of $12.38. The firm has a market capitalization of $296.33 million, a P/E ratio of -3.41 and a beta of 0.43.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.09). Equities analysts expect that Aura Biosciences, Inc. will post -1.66 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AURA. Citigroup reaffirmed an "outperform" rating on shares of Aura Biosciences in a report on Wednesday, March 26th. Lifesci Capital raised Aura Biosciences to a "strong-buy" rating in a report on Friday, January 31st. JMP Securities set a $19.00 price objective on Aura Biosciences in a research report on Wednesday, March 26th. Finally, HC Wainwright set a $25.00 target price on Aura Biosciences in a report on Tuesday, March 25th. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $22.75.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.